DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study.

Clin Infect Dis · 2021 · PMC8326557 · PMID 33569576

Europe PMC DOI

hedged sentence

0.0124

closest p · 0.2× alpha

0.0124

boldest claim

The sentences

borderline significanceP = .0124actually significant

In a post hoc analysis of a subgroup of severely immunocompromised patients in the SO stratum, significant benefit from DAS181 treatment as determined by RTRA proportion at day 28 and a borderline significance for time to RTRA were observed ( P = .0124 and P = .0615, respectively).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.